May 13, 2021
Business News

Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual

WATERTOWN, Mass.–()–Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today presented data from its Phase 2 LANTERN study of LYR-210, the company’s lead long-acting product candidate for chronic rhinosinusitis (CRS), at the Combined Otolaryngology Spring Meetings (COSM) 2021.

LYR-210 is an investigational product candidate designed to be administered in-office and to deliver a sustained release therapeutic for up to six months at difficult-to-access nasal inflammation sites, as a non-invasive alternative…

Click here to view the original article.

Related Posts

You might also like ...

Lunaphore meldet Berufung von Matthias Weber, ehemals President von Leica Biosystems, in den Verwaltungsrat
Universal Display Corporation Announces Participation at Upcoming Conferences
Montrose Environmental Group to Attend Upcoming Investor Conferences